Chronic obstructive pulmonary disease (COPD) MedDRA version: 17.1 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855
Conditions
Interventions
Product Name: CHF 5993 pMDI
Pharmaceutical Form: Pressurised inhalation, solution
INN or Proposed INN: BECLOMETASONE DIPROPIONATE
CAS Number: 5534-09-8
Other descriptive name: BDP
Concentration unit:
Sponsors
Chiesi Farmaceutici S.p.A.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female adults aged = 40 years with written informed consent obtained prior to any study-related procedure. 2. Patients with a diagnosis of COPD (according to GOLD guidelines, updated February 2013) at least 12 months before the screening visit. 3. Current smokers or ex-smokers who quit smoking at least 6 months prior to screening visit, with a smoking history of at least 10 pack years [pack-years = (number of cigarettes per day x number of years)/20] 4. A post-bronchodilator FEV1 =65 years) yes F.1.3.1 Number of subjects for this age range 600
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) Pregnancy testing will be carried out during the course of the study in all women of childbearing potential. Any postmenopausal women or women permanently sterilized can be enrolled in the study. 2. Diagnosis of asthma, history of allergic rhinitis or atopy (atopy which may raise contra-indications or impact the efficacy of the study according to investigator’s judgment). 3. Patients requiring use of the following medications: a. Systemic steroids for COPD exacerbation in the 4 weeks prior to screening. b. A course of antibiotics for COPD exacerbation longer than 7 days in the 4 weeks prior to screening. c. PDE4 inhibitors in the 4 weeks prior to screening. d. Use of antibiotics for a lower respiratory tract infection (e.g pneumonia) in the 4 weeks prior to screening. 4. COPD exacerbation requiring prescriptions of systemic corticosteroids and/or antibiotics or hospitalization during the run-in period. 5. Patients treated with non-cardioselective ß-blockers in the month preceding the screening visit or during the run-in period. 6. Patients treated with long-acting antihistamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study, or if taken as PRN. 7. Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia. 8. Known respiratory disorders other than COPD which may impact the efficacy of the study drug according the investigator’s judgment. 9. Patients who have clinically significant cardiovascular condition. 10. Patients with atrial fibrillation (AF). 11. An abnormal and clinically significant 12-lead ECG that results in active medical problem which may impact the safety of the patient according to investigator’s judgement in consultation with the Corporate Cardiac Leader’s opinion. Patients whose electrocardiogram (ECG) (12 lead) shows QTcF >450 ms for males or QTcF >470 ms for females at screening visit are not eligible. 12. Medical diagnosis of narrow-angle glaucoma, clinically relevant prostatic hypertrophy or bladder neck obstruction that in the opinion of the investigator would prevent use of anticholinergic agents. 13. History of hypersensitivity to M3 Antagonists, ß2-agonist, corticosteroids or any of the excipients contained in any of the formulations used in the trial which may raise contra-indications or impact the efficacy of the study drug according to the investigator’s judgement. 14. Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may impact the efficacy or the safety of the study drug according to investigator’s judgement. 15. Patients with serum potassium levels < 3.5 mEq/L (or 3.5 mmol/L). 16. Unstable concurrent disease, or other which may impact the feasibility of the results of the study according to investigator’s judgment. 17. History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening visit 18. Participation in another clinical trial where investigational drug was received less than 8 weeks prior to screening visit. Patients included in the subset for PK assessment 19. Patients with unsuitable veins for repeated venipuncture. 20. Blood donation (equal or more than 450 mL) or blood loss in the 4 weeks before randomization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To demonstrate the superiority of CHF 5993 pMDI over Tiotropium in terms of moderate and severe COPD exacerbation rate over 52 weeks of treatment.;Secondary Objective: Key secondary objectives: To demonstrate the superiority of CHF 5993 pMDI over Tiotropium in terms of pulmonary function (change from baseline in pre-dose morning FEV1 at Week 52). To demonstrate the non-inferiority of CHF 5993 pMDI relative to CHF 1535 pMDI+Tiotropium in terms of pulmonary function (change from baseline in pre-dose morning FEV1 at Week 52). Secondary objectives: To evaluate the effect of CHF 5993 pMDI on other lung function parameters, patient’s health status and clinical outcome measures. To perform a population PK analysis (in a subset of patients treated with CHF 5993 pMDI) investigating the inter-subject variability in the drug exposure and the effects of selected covariates on PK parameters of B17MP, FF and GB. To collect data in order to assess the impact of study treatments on health economic outcomes. To assess the safety and the tolerability of the study treatments. ;Primary end point(s): Moderate and severe COPD exacerbation rate;Timepoint(s) of evaluation of this end point: in week 52 of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): - Change from baseline in pre-dose morning FEV1 - COPD exacerbation (moderate or severe, rate and time to first) - FEV1 response (change from baseline in pre-dose morning FEV1 = 100 ml) - SGRQ score (change from baseline of total/domain scores) - Use of rescue medication - PK analysis;Timepoint(s) of evaluation of this end point: assessment in week 26 and/or week 52 Plasma levels measured in week 4 | — |
Countries
Argentina, Belarus, Bulgaria, Croatia, Czech Republic, Germany, Hungary, Italy, Mexico, Poland, Romania, Russian Federation, Slovakia, Turkey, Ukraine, United Kingdom
Contacts
Public ContactGeraldine Cohuet
Chiesi Farmaceutici S.p.A.
Outcome results
None listed